Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience
These findings support the long-term effectiveness and safety of benralizumab for EGPA, highlighting its role in inducing clinical remission, reducing corticosteroid dependence, and controlling disease activity.
Authors
- Roberto Padoan (ORCID: https://orcid.org/0000-0002-2356-375X)
- Gabriella Guarnieri (ORCID: https://orcid.org/0000-0003-3664-2024)
- Andrea Vianello (ORCID: https://orcid.org/0000-0002-8790-6029)
- Andrea Doria (ORCID: https://orcid.org/0000-0003-0548-4983)
- Fulvia Chieco Bianchi (ORCID: https://orcid.org/0000-0002-9581-4642)
- Luca Iorio (ORCID: https://orcid.org/0009-0000-2388-7001)
- F. Davanzo (ORCID: https://orcid.org/0009-0004-9429-419X)
- M. Codirenzi
- A. Achille
- Maria Rita Marchi
- Eleonora Fiorin
Institutions
- University of Padua (IT)
- Santa Maria Nuova Hospital (IT)
- Centre hospitalier régional de la Citadelle (BE)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1080/07853890.2025.2581812
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00